Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.
den Dekker WK, Van Mieghem NM, Bennett J, Sabate M, Esposito G, van Bommel RJ, Daemen J, Vrolix M, Cummins PA, Lenzen MJ, Boersma E, Zijlstra F, Diletti R; BioVasc Trial Investigators. den Dekker WK, et al. Among authors: bennett j. Am Heart J. 2020 Sep;227:111-117. doi: 10.1016/j.ahj.2020.06.006. Epub 2020 Jun 15. Am Heart J. 2020. PMID: 32739537 Free article.
Long-term follow-up after percutaneous coronary intervention with polytetrafluoroethylene-covered Symbiot stents compared to bare metal stents, with and without FilterWire embolic protection, in diseased saphenous vein grafts.
Bennett J, Dens J, Stammen F, Coussement P, Janssens L, Claeys M, Vrolix M, Sinnaeve P, Dubois C, Desmet W. Bennett J, et al. Acta Cardiol. 2013 Feb;68(1):1-9. doi: 10.1080/ac.68.1.2959625. Acta Cardiol. 2013. PMID: 23457903 Clinical Trial.
COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial.
Dubois C, Bennett J, Dens J, De Cock D, Desmet W, Belmans A, Ughi GJ, Sinnaeve P, Vrolix M, D'hooge J, Adriaenssens T. Dubois C, et al. Among authors: bennett j. EuroIntervention. 2016 Apr 20;11(13):1457-67. doi: 10.4244/EIJY15M05_02. EuroIntervention. 2016. PMID: 25947278 Free article. Clinical Trial.
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Kandzari DE, et al. Among authors: bennett j. Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26. Lancet. 2017. PMID: 28851504 Clinical Trial.
5-Year clinical follow-up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents) study.
Bennett J, Adriaenssens T, McCutcheon K, Dens J, Desmet W, Sinnaeve P, Vrolix M, Dubois C. Bennett J, et al. Catheter Cardiovasc Interv. 2018 Nov 15;92(6):E375-E380. doi: 10.1002/ccd.27597. Epub 2018 Mar 14. Catheter Cardiovasc Interv. 2018. PMID: 29536609 Clinical Trial.
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Kandzari DE, et al. Among authors: bennett j. J Am Coll Cardiol. 2018 Dec 25;72(25):3287-3297. doi: 10.1016/j.jacc.2018.09.019. Epub 2018 Sep 23. J Am Coll Cardiol. 2018. PMID: 30257191 Free article. Clinical Trial.
Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R. Roguin A, et al. Among authors: bennett j. Circ Cardiovasc Interv. 2018 Oct;11(10):e007331. doi: 10.1161/CIRCINTERVENTIONS.118.007331. Circ Cardiovasc Interv. 2018. PMID: 30354631 Clinical Trial.
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.
Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Hudec M, Poliacikova P, Abdul Ghapar AKB, Selvaraj K, Petrov I, Mylotte D, Pinar E, Moreno R, Fabbiocchi F, Pasupati S, Kim HS, Aminian A, Tie C, Wlodarczak A, Hur SH, Marx SO, Jankovic I, Brar S, Bousquette L, Liu M, Stone GW; ONYX ONE Investigators. Windecker S, et al. N Engl J Med. 2020 Mar 26;382(13):1208-1218. doi: 10.1056/NEJMoa1910021. Epub 2020 Feb 12. N Engl J Med. 2020. PMID: 32050061 Free article. Clinical Trial.
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Kandzari DE, et al. Among authors: bennett j. JACC Cardiovasc Interv. 2020 Jun 8;13(11):1343-1353. doi: 10.1016/j.jcin.2020.02.019. JACC Cardiovasc Interv. 2020. PMID: 32499026 Free article. Clinical Trial.
5,671 results